10.03

4.39% -0.46

After Hours: 10.04 0.010 +0.10%

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $10.03, with a volume of 1.35M. It is down -4.39% in the last 24 hours and down -4.39% over the past month. Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Previous Close:

$10.49

Open:

$10.48

24h Volume:

1.35M

Relative Volume:

1.10

Market Cap:

$592.92M

Revenue:

$106.47M

Net Income/Loss:

$82.89M

P/E Ratio:

6.7153

EPS:

1.4936

Net Cash Flow:

$-2.43M

1W Performance:

-8.90%

1M Performance:

-4.39%

6M Performance:

+16.63%

1Y Performance:

+17.04%

1-Day Range:

$10.01

$10.73

1-Week Range:

$10.01

$11.16

52-Week Range:

$7.16

$13.16

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(888) 958-1253

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	10.03	620.12M	106.47M	82.89M	-2.43M	1.4936
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	BTIG Research	Buy
Jul-02-25	Initiated	H.C. Wainwright	Buy
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

May 23, 2026

Lightning eMotors Inc. (ZEV) - Minichart

May 23, 2026

May 22, 2026

ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill

May 22, 2026

May 19, 2026

ZVRA: AI-driven patient identification and global expansion fuel growth and pipeline acceleration - TradingView

May 19, 2026

May 18, 2026

Understanding Momentum Shifts in (ZVRA) - Stock Traders Daily

May 18, 2026

Zevra Therapeutics CEO to present company updates at H.C. Wainwright BioConnect Investor Conference - Traders Union

May 18, 2026

May 17, 2026

Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event - Traders Union

May 17, 2026

Did One-Off-Boosted Q1 Profits Just Shift Zevra Therapeutics' (ZVRA) Investment Narrative? - Sahm

May 17, 2026

May 15, 2026

A Look At Zevra Therapeutics (ZVRA) Valuation After Strong Earnings And SDX Portfolio Sale - Sahm

May 15, 2026

May 14, 2026

EDGAR Filing Documents for 0001434647-26-000021 - SEC.gov

May 14, 2026

May 13, 2026

Zevra Therapeutics (ZVRA) legal chief sells 1,794 shares under 10b5-1 plan - Stock Titan

May 13, 2026

Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear - Yahoo Finance

May 13, 2026

May 12, 2026

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference - The Manila Times

May 12, 2026

May 11, 2026

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

May 11, 2026

May 10, 2026

Zevra Therapeutics Earnings Call Highlights Growth Pivot - TipRanks

May 10, 2026

May 09, 2026

Number of shareholders of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView

May 09, 2026

Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed - Sahm

May 09, 2026

Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance

May 09, 2026

May 08, 2026

Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25 - Moomoo

May 08, 2026

ZVRA Maintained by Guggenheim -- Price Target Raised to $25.00 - GuruFocus

May 08, 2026

Zevra Therapeutics price target raised to $25 from $23 at Guggenheim - TipRanks

May 08, 2026